ClinicalTrials.gg
Active, not recruitingNCT05117840SHIELDUpdated Jul 6, 2026

Screening for High Frequency Malignant Disease

An observational study in Lung Cancer, sponsored by Guardant Health, Inc.. Active, not recruiting at 143 sites in 3 countries. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Guardant Health, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
12,000
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,462 studies in Lung Neoplasms with a site in United States — 423 open to participants now, 644 under way, 52 of them phase 3. Lung Neoplasms · United States.

Planned enrollment
14th of 442
12,000 · median 123
Started
2022
with 118 others
Observational
443 of 2,462
95 open now
Primary completion
2026-12
later than 146 of 638 live
Registered
1,903rd of 2,462
by date

Among the 2,462 studies in Lung Neoplasms with a site in United States, this one is the 14th largest by planned enrollment of the 442 observational ones that give a count, is one of 119 that started in 2022, is one of 443 observational ones, reaches primary completion later than 146 of the 638 other live ones, and was the 1,903rd registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

423 of the 2,462 studies in Lung Neoplasms with a site in United States are open now. Recruiting first, the newest first:

418 more — sign in →

All 423 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,462 studies in Lung Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.

Read the detailed description

The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.

The SHIELD study will recruit patients in separate cancer-risk cohorts with specified pathways for cancer screening. Patients eligible for high frequency cancer screening will be screened for study eligibility per each cohort's criteria (see appendixes). Within each cohort, individuals eligible for the study will be consented for the investigational blood draw and applicable questionnaires within 90 days of standard of care screening method and prior to any invasive procedure for cancer diagnosis and/or treatment (T0). Subjects will have at least 2 follow-up visits at 1 year and 2 years (T1 and T2) since the index blood draw during the study. Additional follow-up is defined per each cohort. Updated medical data, repeat investigational blood draw and study questionnaires will be collected at follow-up intervals per each cohort's study procedure.

The first cohort to be recruited will be designated as cohort A for lung cancer screening (appendix 1). Additional baskets with other cancer-risk cohorts of interest will be considered and added as the study expands. Additional appendixes will be designed for these cohorts at that time.

03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • Screening
  • Non-invasive diagnostics
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The SHIELD study will recruit patients in separate cancer-risk cohorts with specified pathways for cancer screening. Patients eligible for high frequency cancer screening will be screened for study eligibility per each cohort's criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged 50-80 years at time of consent
  • Increased risk of lung cancer defined by: at least 20 pack-year smoking history and currently smoke or have quit within the past 15 years
  • Undergoing or intended to undergo low dose CT scan of the chest for lung cancer screening
  • Willing to consent to the blood draw during index LDCT screening visit and before any invasive procedures or treatment for lung cancer diagnosis
  • Willing to consent to a 1-year and additional follow-up per protocol

Exclusion criteria

Exclusion Criteria:

  1. Subject has quit smoking for 15 or more years
  2. Subject has less than 20 pack-year smoking history
  3. Subject has a health problem that substantially limits and/or the ability or willingness to have curative lung surgery
  4. Subject undergoing low-dose CT scan of the chest for investigation of symptoms suspicious for lung cancer
  5. Preexisting or history of lung cancer
  6. Previously diagnosed high-risk lung lesion
  7. History of any (subjects who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of for the study)
  8. Currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs
  9. Currently receiving treatment for pneumonia
  10. Any major physical trauma (e.g., disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent
  11. Known medical condition which, in the opinion of the investigator, should preclude enrollment into the study
  12. Participation in a clinical research study in which an experimental medication and/or medical procedure has been administered or may be administered within the 30 days leading up to providing informed consent or may be administered through the time of subject screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
12,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Lung Cancer Screening Cohort

    Individuals at high-risk of lung cancer undergoing standard of care screening as per USPSTF guidelines. All subjects will undergo low-dose CT scanning as per guidelines and an investigational blood-draw will be taken from all enrolled subjects.

    Device: Low-dose CT scan

Interventions

  • DeviceLow-dose CT scan

    Standard of care screening for individuals at high-risk of lung cancer

06

What researchers measure

Primary outcomes

  1. Performance characteristics of Guardant LUNAR-2 test

    Sensitivity, specificity, NPV, PPV

    Time frame: 36 months

Secondary outcomes

  1. Screen detected cancer rate

    To estimate the number of screen detected cancers, early-stage and late-stage screen detected cancers per 1000 screened subjects

    Time frame: 36 months

07

Study locations

143 sites
  • University of Alabama Birmingham Lung Health Center
    Birmingham, Alabama 35233, United States
  • Highlands Oncology Group PA
    Fayetteville, Arkansas 72703, United States
  • Pacific Cancer Medical Center
    Anaheim, California 92801, United States
  • Providence St. Joseph Hospital Eureka Cancer Program
    Eureka, California 95501, United States
  • SoCal Clinical Research
    Fountain Valley, California 92708, United States
  • Advanced Investigative Medicine
    Hawthorne, California 90250, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • California Medical Research Associates Inc.
    Northridge, California 91324, United States
  • Providence Medical Foundation
    Santa Rosa, California 95403, United States
  • Starling Physicians
    New Britain, Connecticut 06051, United States
  • George Washington University Medical Center
    Washington D.C., District of Columbia 20037, United States
  • Central Florida Pulmonary Group, P.A.
    Altamonte Springs, Florida 32701, United States
  • Pulmonary, Critical Care & Sleep Disorders Institute of South Florida
    Atlantis, Florida 33462, United States
  • CTMD Research
    Coconut Creek, Florida 33063, United States
  • Life Arc Research Centers
    Coral Gables, Florida 33134, United States
  • Pulmonary Physicians of South Florida, LLC
    Coral Springs, Florida 33065, United States
  • SIMED Health, LLC
    Gainesville, Florida 32607, United States
  • National Research Institute
    Hialeah, Florida 33013, United States
  • 3Sync Research
    Hialeah, Florida 33016, United States
  • Zenith Clinical Research
    Hollywood, Florida 33024, United States
  • Multi-Specialty Research Associates, Inc.
    Lake City, Florida 32055, United States
  • 3Sync Research
    Lake Worth, Florida 33460, United States
  • Adtremed INC
    Lutz, Florida 33548, United States
  • Las Mias Research and Medical Center
    Miami, Florida 33144, United States
  • Monzon Clinical Trials
    Miami, Florida 33144, United States
  • Valencia Medical and Research Center
    Miami, Florida 33165, United States
  • Miami Pulmonary Specialists
    Miami, Florida 33173, United States
  • Florida Research Center, Inc.
    Miami, Florida 33174, United States
  • Charisma Medical and Research Center
    Miami Lakes, Florida 33014, United States
  • Adult Medicine of Lake County
    Mt. Dora, Florida 32757, United States
  • Central Florida Pulmonary Group, P.A.
    Orlando, Florida 32803, United States
  • Central Florida Pulmonary Group, P.A.
    Orlando, Florida 32825, United States
  • CTMD Research
    Palm Springs, Florida 33406, United States
  • Coastal Pulmonary and Critical Care, P.L.C.
    St. Petersburg, Florida 33704, United States
  • Adtremed Research Clinic
    Tampa, Florida 33607, United States
  • VICIS Clinical Research
    Tampa, Florida 33615, United States
  • Midtown OB/GYN North
    Columbus, Georgia 31901, United States
  • Pulmonary and Sleep Specialists of Northeast Georgia, PC
    Dacula, Georgia 30019, United States
  • DC Research Works
    Marietta, Georgia 30060, United States
  • Randomize Now, LLC
    Peachtree City, Georgia 30269, United States
  • Pulmonary and Sleep Specialists of Northeast Georgia, PC
    Winder, Georgia 30680, United States
  • Christie Clinic
    Champaign, Illinois 61822, United States
  • Eagle Clinical Research
    Chicago, Illinois 60621, United States
  • Hutchinson Clinic - North Waldron
    Hutchinson, Kansas 67502, United States
  • MedCorps Asthma and Pulmonary Specialists
    Maysville, Kentucky 41056, United States
  • Family Medicine Physicians
    Hammond, Louisiana 70403, United States
  • Willis-Knighton Cancer Center
    Shreveport, Louisiana 71103, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • HealthPartners Institute
    Minneapolis, Minnesota 55440, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Memorial Hospital at Gulfport
    Gulfport, Mississippi 39501, United States
  • Olive Branch Family Medical Center
    Olive Branch, Mississippi 38654, United States
  • Family Medical Clinic of North Mississippi
    Southaven, Mississippi 38672, United States
  • Branson Pulmonology and Sleep Medicine
    Branson, Missouri 65616, United States
  • Washington University School of Medicine/Barnes-Jewish Hospital
    St Louis, Missouri 63310, United States
  • Somnos Clinical Research
    Lincoln, Nebraska 68510, United States
  • Great Plains Health
    North Platte, Nebraska 69101, United States
  • Ocean Pulmonary Associates
    Brick, New Jersey 08724, United States
  • Ocean University Medical Center
    Brick, New Jersey 08724, United States
  • RespaCare
    Bridgewater, New Jersey 08807, United States
  • MedCorps Asthma and Pulmonary Specialists
    Cape May Court House, New Jersey 08210, United States
  • Pulmonary & Sleep Disorders of New Jersey
    East Brunswick, New Jersey 08816, United States
  • JFK University Medical Center
    Edison, New Jersey 08820, United States
  • Pulmonary Internists
    Edison, New Jersey 08820, United States
  • Pulmonary Specialists of North Jersey
    Englewood, New Jersey 07631, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • MedCorps Asthma and Pulmonary Specialists
    Linwood, New Jersey 08221, United States
  • Pulmonary & Sleep Disorders of New Jersey
    Monroe, New Jersey 08831, United States
  • John Theurer Cancer Center at Jersey Shore University Medical Center
    Neptune City, New Jersey 07753, United States
  • Pulmonary Specialists of North Jersey
    North Bergen, New Jersey 07047, United States
  • Respiratory and Sleep Specialists, LLC
    Princeton, New Jersey 08540, United States
  • Riverview Medical Center
    Red Bank, New Jersey 07701, United States
  • North Jersey Pulmonary Associates
    Ridgewood, New Jersey 07450, United States
  • MedCorps Asthma and Pulmonary Specialists
    Sewell, New Jersey 08080, United States
  • Ocean Pulmonary Associates
    Toms River, New Jersey 08755, United States
  • Long Island Pulmonary and Sleep Medicine Associates
    Hempstead, New York 11550, United States
  • Long Island Pulmonary and Sleep Medicine Associates
    Rockville Centre, New York 11570, United States
  • Great Lakes Medical Research
    Westfield, New York 14787, United States
  • CTMD Research, Asheville
    Asheville, North Carolina 28804, United States
  • MacGregor Family Physicians, P.A.
    Cary, North Carolina 27518, United States
  • Durham VA Medical Center
    Durham, North Carolina 27705, United States
  • Clinical Research of Gastonia
    Gastonia, North Carolina 28054, United States
  • Peters Medical Research
    High Point, North Carolina 27262, United States
  • Piedmont Healthcare
    Statesville, North Carolina 28625, United States
  • Wilmington Health
    Wilmington, North Carolina 28401, United States
  • Lillestol Research, LLC
    Fargo, North Dakota 58104, United States
  • Pulmonology Associates Inc.
    Broomall, Pennsylvania 19008, United States
  • Advocare Pulmonary And Sleep Specialists
    Exton, Pennsylvania 19341, United States
  • Advocare Pulmonary And Sleep Specialists
    Lansdale, Pennsylvania 19446, United States
  • Pulmonology Associates Inc.
    Paoli, Pennsylvania 19301, United States
  • Advocare Pulmonary And Sleep Specialists
    West Chester, Pennsylvania 19380, United States
  • Pulmonology Associates Inc.Pulmonology Associates Inc. (Suite 108)
    Wynnewood, Pennsylvania 19096, United States
  • Pulmonology Associates Inc.
    Wynnewood, Pennsylvania 19096, United States
  • Berks Schuylkill Respiratory Specialists, Ltd.
    Wyomissing, Pennsylvania 19610, United States
  • Vista Clinical Research
    Columbia, South Carolina 29201, United States
  • The Jackson Clinic
    Jackson, Tennessee 38305, United States
  • Midsouth Independent Group
    Memphis, Tennessee 38104, United States
  • Midsouth Independent Group
    Memphis, Tennessee 38106, United States
  • Midsouth Independent Group
    Memphis, Tennessee 38114, United States

Showing the first 100 of 143 sites across 3 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Dec 2026, 59 months after the start.

Of 90 industry-sponsored observational studies under Lung Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 58. This study's planned 59 months is above that.

Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2021
First posted
Nov 11, 2021
StartActual
Jan 13, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05117840
Lead sponsor
Guardant Health, Inc.
Responsible party
Sponsor
First posted
Nov 11, 2021
Start date
Jan 13, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 6, 2026

Study contacts

Hannah Oakley
study director · Guardant Health, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion